Bendamustine for treatment of chronic lymphocytic leukemia

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 10, 2012, Pages 1495-1505

  Chang, Julie Elizabeth ^a   Kahl, Brad Steven ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Bendamustine; Chemotherapy; Chronic lymphocytic leukemia; Small lymphocytic lymphoma

Indexed keywords

5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; ALKYLATING AGENT; ALLOPURINOL; ANTHRACYCLINE; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A2; DOXORUBICIN; FLUDARABINE; IBRUTINIB; LENALIDOMIDE; MELPHALAN; MITOXANTRONE; NAVITOCLAX; OBINUTUZUMAB; OFATUMUMAB; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EXCISION REPAIR; FAILURE FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FECES INCONTINENCE; FOLLICULAR LYMPHOMA; GOVERNMENT REGULATION; HEADACHE; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; LEUKEMIA RELAPSE; LIVER DYSFUNCTION; MANTLE CELL LYMPHOMA; MENTAL HEALTH; MITOSIS INHIBITION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PROGRESSION FREE SURVIVAL; RASH; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; URINE INCONTINENCE; VOMITING; WEAKNESS;

ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NITROGEN MUSTARD COMPOUNDS;

EID: 84863101100     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.693163     Document Type: Article

References (68)

1. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43(9):1755-62
2. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29(26):3559-66
3. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study. Cancer 2010;116(1):106-14
4. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26(2):204-10
5. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26(27):4473-9
6. American Cancer Society: Cancer Facts & Figures 2012. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-031941.pdf [Accessed 13 February 2012]
7. Bendamustine (Treanda) package insert. Available from: http://www.treanda.com/pdf/TREANDA-final-PI.pdf [Accessed 11 February 2012]
8. Dennie TW, Kolesar JM. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther 2009;31(Pt 2):2290-311
9. Cheson BD, Rummel MJ. Bendamustine: Rebirth of an old drug. J Clin Oncol 2009;27(9):1492-501
10. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14(1):309-17
11. Gandhi V. Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies. Semin Oncol 2002;29(4 Suppl 13):4-11
12. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007;59(6):759-70
13. Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010;66(6):1039-49
14. Teichert J, Sohr R, Baumann F, et al. Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005;33(7):984-92
15. Matthias M, Preiss R, Sohr R, et al. Pharmacokinetics of bendamustine in patients with malignant tumors [abstract #1467]. J Clin Oncol 1995;14:458a
16. Teichert J, Mockel J, Ponisch W. Influence of hepatic and renal function on the pharmacokinetics of bendamustine. Int J Clin Pharm Ther 2003;41:564
17. Preiss R, Teichert B, Ponisch W, et al. Bendamustine in patients with renal insufficiency (abstract). Onkologie 2003;26:717
18. Schoppmeyer K, Kreth F, Wiedmann M, et al. A pilot study of bendamustine in advanced bile duct cancer. Anticancer Drugs 2007;18(6):697-702
19. Schwanen C, Hecker T, Hubinger G, et al. in vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002;16(10):2096-105
20. Chow KU, Boehrer S, Geduldig K, et al. in vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001;86(5):485-93
21. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 2002;87(1):33-43
22. Weide R, Mergenthaler U, Friesenhahn V, et al. Bendamustine/mitoxantrone/ rituximab: A short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(9):1468-74
23. Weide R, Pandorf A, Heymanns J, Koppler H. Bendamustine/Mitoxantrone/ Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004;45(12):2445-9
24. Schmidt-Hieber M, Busse A, Reufi B, et al. Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro. J Cancer Res Clin Oncol 2009;135(2):227-34
25. Tsimberidou AM, Wen S, O'Brien S, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol 2007;25(29):4648-56
26. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90(10):1357-64
27. Koenigsmann M, Knauf W, Herold M, et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma-a multicenter phase I/II trial of the east german society of hematology and oncology (OSHO). Leuk Lymphoma 2004;45(9):1821-7
28. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin'-rfsti lymphomas. Anticancer Drugs 2001;12(9):725-9
29. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated lowgrade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002;128(11):603-9
30. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II Trial of the German CLL Study Group (GCLLSG). ASH Annu Meeting Abstr 2009;114(22):205
31. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27(26):4378-84
32. U.S. National Institutes of Health/National Cancer Institute. NCT identifier, NCT00769522 Available from: http://www.clinicaltrials.gov [Accessed 20 February 2012]
33. Rituximab (Rituxan) package insert. Available from: http://www.gene.com/ gene/products/information/pdf/rituxanprescribing. pdf [Accessed 13 February 2012]
34. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58(1):25-32
35. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333(24):1600-7
36. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127(1):3-11
37. Cheson BD, Kroll ML. Bendamustine induced neurotoxicity. Clin Adv Hematol Oncol 2009;7(11):743-6
38. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: A review. J Clin Oncol 1994;12(10):2216-28
39. Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998;16(5):1885-9
40. Glance LE, Cumpston A, Kanate A, Remick SC. Bendamustine-associated hemolytic anemia. Ann Pharmacother 2009;43(11):1903-6
41. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annu Meeting Abstr 2009;114(22):405
42. European Medicines Agency website. Available from: http://wwwemaeuropaeu/ [Accessed 11 February 2012]
43. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343(24):1750-7
44. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002;99(10):3554-61
45. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25(35):5616-23
46. Rai KR, Coutre S, Rizzieri D, et al. Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis [abstract 1538]. Blood 2001;98:365a
47. Sharman J, de Vos S, Leonard JP, et al. A phase I study of the selective phosphatidylinositol 3-kinase-delta (PI3K {delta}) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). ASH Annu Meeting Abstr 2011;118(21):1787
48. Kipps TJ, Swinnen LJ, Wierda WG, et al. Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A phase I study in patients with relapsed/refractory Chronic Lymphocytic Leukemia (CLL). ASH Annu Meeting Abstr 2011;118(21):3904
49. Byrd JC, Blum KA, Burger JA, et al. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. ASCO Meeting Abstr 2011;29(15 Suppl):6508
50. U.S. National Institutes of Health/National Cancer Institute. NCT identifier NCT01292135 Available from: http://www.clinicaltrials.gov [Accessed 20 February 2012]
51. Fowler NH, Kahanic SP, Forero A, et al. Results of a phase II study with bendamustine and ofatumumab in untreated indolent B-cell non-Hodgkin's lymphoma. ASH Annu Meeting Abstr 2011;118(21):778
52. Ujjani CS, Gehan EA, Ramzi P, et al. Ofatumumab and bendamustine in previously treated CLL and SLL. ASH Annu Meeting Abstr 2011;118(21):4615
53. Lemery SJ, Zhang J, Rothmann MD, et al. U.S. food and drug administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010;16(17):4331-8
54. Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (Obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS Study. ASH Annu Meeting Abstr 2011;118(21):269
55. Salles GA, Morschhauser F, Thieblemont C, et al. Efficacy and safety of obinutuzumab (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma: Results from a phase I/II study (BO20999). ASH Annu Meeting Abstr 2011;118(21):268
56. U.S. National Institutes of Health/National Cancer Institute. NCT identifier NCT01300247 Available from: http://www.clinicaltrials.gov [Accessed 20 February 2012]
57. U.S. National Institutes of Health/National Cancer Institute. NCT identifier NCT01010568 Available from: http://www.clinicaltrials.gov [Accessed 20 February 2012]
58. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111(11):5291-7
59. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 2006;24(34):5343-9
60. U.S. National Institues of Health/National Cancer Institute. NCT identifier NCT00974233 Available from: http://www.clinicaltrials.gov [Accessed 20 February 2012]
61. Fowler NH, McLaughlin P, Kwak L, et al. Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. ASCO Meeting Abstr 2009;27(15S):8548
62. Fowler NH, McLaughlin P, Hagemeister FB, et al. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. ASCO Meeting Abstr 2010;28(15 Suppl):8036
63. Ferrajoli A, Badoux X, O'Brien S, et al. the Combination of lenalidomide and rituximab induces complete and partial responses in patients with relapsed and refractory chronic lymphocytic leukemia. ASH Annu Meeting Abstr 2010;116(21):1395
64. Personal communication, J.E. Chang (University of Wisconsin). Industry-sponsored studies of rituximab and lenalidomide maintenance therapy following bendamustine and rituximab induction chemoimmunotherapy in relapsed/refractory and previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma: Planned phase II studies through the Wisconsin Oncology Network
65. U.S. National Institutes of Health/National Cancer Institute. NCT identifier, NCT00602459 Available from: http://www.clinicaltrials.gov [Accessed 30 April 2012]
66. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006;132(2):99-104
67. van der Jagt RH, Cohen P, Cheson B, et al. Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma. Blood 2006;108(11):abstract 2710
68. Friedberg JW, Vose JM, Kelly JL, et al. Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell Non-Hodgkin Lymphoma (NHL): A multicenter phase II clinical trial. ASH Annu Meeting Abstr 2009;114(22):924